From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

What is Ibrutinib?

Ibrutinib structure.svg

What are the uses of this medicine?

This medicine is used to treat adults with:

How does this medicine work?

  • Ibrutinib is a small-molecule inhibitor of BTK.
  • Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity.
  • BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.
  • BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion.
  • Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

Who Should Not Use this medicine ?

  • This medicine have no usage limitations.

What drug interactions can this medicine cause?

  • Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors.
  • Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) .
  • Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A.
  • Avoid coadministration with strong CYP3A inducers (eg:(eg: rifampin, carbamazepine, phenytoin, St. John’s wort)

Is this medicine FDA approved?

  • It was approved for use in the United States in 2014.

How should this medicine be used?

Recommended Dosage: Mantle Cell Lymphoma and Marginal Zone Lymphoma

  • The recommended dosage of IMBRUVICA for MCL and MZL is 560 mg orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia

  • The recommended dosage of IMBRUVICA for CLL/SLL and WM is 420 mg orally once daily until disease progression or unacceptable toxicity.
  • For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR).
  • For WM, IMBRUVICA can be administered as a single agent or in combination with rituximab.

Chronic Graft versus Host Disease

  • The recommended dosage of IMBRUVICA for cGVHD is 420 mg orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity.


  • Take IMBRUVICA exactly as your healthcare provider tells you to take it.
  • Take IMBRUVICA 1 time a day.
  • Swallow IMBRUVICA capsules or tablets whole with a glass of water.
  • Do not open, break, or chew IMBRUVICA capsules.
  • Do not cut, crush, or chew IMBRUVICA tablets.
  • Take IMBRUVICA at about the same time each day.
  • If you miss a dose of IMBRUVICA take it as soon as you remember on the same day. Take your next dose of IMBRUVICA at your regular time on the next day. Do not take extra doses of IMBRUVICA to make up for a missed dose.
  • If you take too much IMBRUVICA call your healthcare provider or go to the nearest hospital emergency room right away.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

  • As Capsules: 70 mg and 140 mg
  • Tablets: 140 mg, 280 mg, 420 mg, and 560 mg

This medicine is available in fallowing brand namesː


What side effects can this medication cause?

The most common side effects of IMBRUVICA in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:

The most common side effects of IMBRUVICA in adults with cGVHD include:

IMBRUVICA may cause serious side effects, including:

What special precautions should I follow?

  • Fatal bleeding events have occurred in patients who received IMBRUVICA. Monitor for bleeding and manage.
  • Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA therapy. Monitor patients for fever and infections, evaluate promptly, and treat.
  • Cytopenias may occur. Check complete blood counts monthly.
  • Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA. Monitor for symptoms of arrhythmias and cardiac failure and manage.
  • Hypertension occurred in 19% of 1,476 patients who received IMBRUVICA. Monitor blood pressure and treat.
  • Other malignancies have occurred in patients, including skin cancers, and other carcinomas.
  • Tumor lysis syndrome has been infrequently reported with IMBRUVICA. Assess baseline risk and take precautions. Monitor and treat for TLS.
  • IMBRUVICA Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

What to do in case of emergency/overdose?

Management of overdosage:

  • Closely monitor patients who ingest more than the recommended dosage and provide appropriate supportive treatment.

Can this medicine be used in pregnancy?

  • IMBRUVICA can cause fetal harm based on findings from animal studies.
  • There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.

Can this medicine be used in children?

  • The safety and effectiveness of IMBRUVICA in pediatric patients has not been established.

What are the active and inactive ingredients in this medicine?

  • Active ingredient: ibrutinib
  • Inactive ingredients:
  • IMBRUVICA capsules: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The 70 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and black ink. The 140 mg capsule shell contains gelatin, titanium dioxide, and black ink.
  • IMBRUVICA tablets: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg and 560 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg, 420 mg, and 560 mg tablets).

Who manufactures and distributes this medicine?

Distributed and Marketed by: Pharmacyclics LLC Sunnyvale

  • Marketed by: Janssen Biotech, Inc. Horsham, PA USA

What should I know about storage and disposal of this medication?

  • Store IMBRUVICA capsules and tablets at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep IMBRUVICA capsules in the original container with the lid tightly closed.
  • Keep IMBRUVICA tablets in the original carton.
  • Keep IMBRUVICA and all medicines out of the reach of children.

Cost and Coupons - Ibrutinib

Reviews for Ibrutinib

Learn more about Ibrutinib

Latest research - Ibrutinib

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Ibrutinib is a stub. If you are familiar with the topic Ibrutinib, you can help us. Paid editors welcome!


Ibrutinib is part of WikiMD's free ^articles!

^Ibrutinib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Overweight?. W8MD's physician weight loss & sleep medicine program can HELP. Philadelphia lose weight. NYC lose weight Tele weight loss available